8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________________________

FORM 8-K

_____________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 11, 2023

_____________________________________________

ENVISTA HOLDINGS CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

_____________________________________________

Delaware

(State or Other Jurisdiction of Incorporation)

(714) 817-7000

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

_____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | --- | --- || ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | --- | --- || ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | --- | --- || ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | --- | --- |

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company      ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On December 11, 2023, Envista Holdings Corporation (the “Company”) and Patrik Eriksson, the Company’s SVP and President, Nobel Biocare, mutually agreed that Mr. Eriksson’s employment will terminate effective December 31, 2023.

ITEM 7.01 REGULATION FD

On December 14, 2023, the Company issued a press release announcing recent appointments to the Company’s leadership team. A copy of the release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.

The information included or incorporated by reference in this Item 7.01 is being furnished to the SEC and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Document

Exhibit 99.1

Envista Holdings Corporation Appoints Three New Members to Leadership Team

BREA, Calif., -- Envista Holdings Corporation (NYSE: NVST) today announced the expansion of its leadership team, with the recent appointments of Robert Befidi as President, Diagnostics; Suraj Satpathy as Chief Human Resources Officer; and Andrew Chen as Chief Information Officer.

Robert Befidi joins Envista from 3M, where he most recently was President of the Separation and Purification Sciences Division, a global filtration technology leader. He has held several senior executive roles in the 3M Health Care Business Group, including leading Global Marketing, Strategy, M&A, and Data Security & Compliance. Before 3M, Robert worked in private equity, consulting, tech, and investment banking research. He co-founded Gordian Capital, a private equity company where he led capital raising, deal origination, industry research, transaction structuring, and portfolio management.

Suraj Satpathy joins Envista Holdings Corporation from Cepheid, a global diagnostics company under the Danaher Corporation, where he most recently served as the Senior Vice President of Human Resources and Internal Communications. Suraj joined Cepheid in 2021 and was instrumental in supporting the company's hypergrowth by building leadership capabilities and talent processes, shaping culture, and scaling HR infrastructure. Before Cepheid, Suraj spent nearly 14 years at Gilead Sciences, where he held various human resources leadership roles, including Vice President of Human Resources for Europe, Middle East, Australia, and Canada.

Andrew Chen joins Envista from Kite Pharma, an industry leading cell therapy biotech, where he most recently was Chief Information Officer. Prior to Kite, Andrew held senior Information Technology leadership positions across multiple industries, including Seattle Genetics, AstraZeneca, JP Morgan Chase, DuPont, and Bank of America. Andrew brings over 30 years’ experience in IT, with the last 17 years in the healthcare industry, spanning Asia, Europe, LATAM, and US.

Patrik Eriksson, Nobel Biocare current president, will depart the organization December 31, 2023 to pursue other opportunities. Amir Aghdaei, CEO Envista, is working directly with the Nobel Biocare leadership team to expand the business’ capabilities and accelerate growth in 2024 until a permanent successor is named.

“Envista and our customers will benefit from the leadership and expertise of Robert, Andrew, and Suraj,” said Amir. “We intend to digitize, personalize, and democratize oral care and I am confident the expansion of our leadership capabilities with these individuals will further enhance our core values of customer centricity, innovation, respect, continuous improvement, and leadership. Furthermore, on behalf of the entire Envista team, I want to thank Patrik Eriksson for his 11+ years of dedicated service to the company and our customers.”

Additionally, an external search for the Chief Financial Officer position is underway as we look to appoint a permanent successor in the near future.

ABOUT ENVISTA HOLDINGS CORPORATION

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.

FOR FURTHER INFORMATION

Melissa Morrison  Vice President, Communication

Envista Holdings Corporation  200 S. Kraemer Blvd., Building E  Brea, CA 92821  Telephone: (714) 817-7000

SOURCE Envista Holdings Corporation